Determination of the antimicrobial property of oregano (Plectranthus amboinicus (Lour.) Spreng.) crude aqueous leaf extract against throat pathogens using broth and checkerboard dilution methods

@#<p style="text-align: justify;"><strong>Objective:</strong> This study aimed to determine the antimicrobial property of oregano (Plectranthus amboinicus) crude leaf extract against pathogens that infect the throat, specifically Streptococcus pyogenes and Candida albicans using the broth and checkerboard dilution methods.</p><p style="text-align: justify;"><strong>Methods:</strong> This study employed an experimental study design using broth dilution method for the determination of the minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) against Streptococcus pyogenes ATCC 19615, and minimum fungicidal concentration (MFC) against Candida albicans ATCC 14053 of P. amboinicus crude extract (PA extract). Checkerboard dilution method was then used for determination of the synergy between PA extract and the standard antimicrobials.</p><p style="text-align: justify;"><strong>Results:</strong> In vitro growth inhibition of S. pyogenes (MIC 0.13 g/mL) and C. albicans (MIC 0.03 g/mL) was exhibited by the PA extract. The highest concentration of PA extract used in this study was not sufficient to demonstrate bactericidal and fungicidal activity (MBC >0.25 g/mL, MFC >0.25 g/mL). Results of checkerboard dilution method revealed that PA extract when combined with either penicillin (for S. pyogenes) or nystatin (for C. albicans) demonstrated indifference.</p><p style="text-align: justify;"><strong>Conclusion:</strong> The crude extract of Plectranthus amboinicus has the capability to inhibit the growth of both S. pyogenes and C. albicans. This demonstrates its potential use in the treatment of throat infections caused by these organisms.</p><p style="text-align: justify;"><strong>Key Words:</strong> Plectranthus amboinicus, oregano, antimicrobial, throat infections, herbal medicine</p>

Complementary and alternative medicine use and quality of life among Filipino Adult Psoriasis Vulgaris Patients seen in a tertiary center: A cross-sectional study

Objective@#To determine the prevalence of complementary and alternative medicine (CAM) use and its association with quality of life (QOL) among Filipino adult psoriasis vulgaris patients. @*Methods@#A cross-sectional study was conducted in an outpatient dermatology department of a tertiary hospital, using a semi-structured, interview-guided questionnaire, and a self-administered QOL questionnaire, the dermatology life quality index (DLQI). @*Results@#A total of 135 Filipino adult patients with psoriasis vulgaris were included. The prevalence of CAM use was 47%, with most CAM users being female and single. Completion of tertiary education was found significantly associated with CAM use (p < 0.05). A greater body surface area involvement and longer disease duration were more common among CAM users but these were not statistically significant. Special diet (56.3%) was the most commonly used type of CAM, followed by herbal medicine (46.9%), bath therapy (18.9%) and faith healing (12.5%). Major sources of CAM information were families (43.8%), internet/social media (28.1%) and health professionals (25%). Around 40% of the participants used CAM out of curiosity. The mean DLQI score of the respondents was 11.3 (±7.3) corresponding to poor quality of life. CAM use was significantly associated with negative impact on physical symptoms and feelings, daily activities, and work and school (P = 0.044; P = 0.019; P = 0.047). After adjusting for confounding variables, patients with poor QOL were twice more likely to use CAM but this was not statistically significant (odds ratio [OR], 1.76; 95% confidence interval [CI], 0.78-3.95; P = 0.17). @*Conclusions@#The use of CAM is prevalent among Filipino adult patients with psoriasis vulgaris. The significant association between CAM use and a poor quality of life may reflect the unmet physical and psychosocial needs of patients. A patient-perspective approach should acknowledge the reasons for CAM use, which could guide the physicians in imparting available scientific evidence, or the lack thereof, for the use of CAM to these patients.

Intralesional measles, mumps, and rubella vaccine for cutaneous warts: A systematic review and meta-analysis

BACKGROUND: Warts, caused by the human papilloma virus (HPV), are mucocutaneous proliferations controlled by cell-mediated immunity. Intralesional immunotherapy with measles, mumps, and rubella (MMR) vaccine, is postulated to induce a higher immune response for clearance of lesions.OBJECTIVE: To assess the efficacy, safety and effect on recurrence of intralesional MMR vaccine for the treatment of warts.METHODS: We searched online databases for randomized controlled trials on intralesional MMR vaccine for warts. Effects measured were the complete clearance of target and distant warts, adverse events noted and recurrence after treatment duration.RESULTS: Four RCTs comparing intralesional MMR vaccine and placebo were assessed. Meta-analysis showed a risk ratio of 0.24 [95% CI: 0.18, 0.34] favoring intralesional MMR vaccine and a highly significant difference in completely clearing target warts (P-value CONCLUSIONS: Intralesional MMR vaccine significantly reduces and clears target and distant warts as compared to placebo. It is a generally safe intervention with lasting effect assessed up to 6 months follow-up.

Reduced levels of serum 25-hydroxyvitamin D in alopecia areata: A systematic review and meta-analysis

@#<p><strong>BACKGROUND:</strong> Alopecia areata is postulated to be an autoimmune disease of which vitamin D may play a role being found in the immune system and hair.</p><p><strong>OBJECTIVE:</strong> To determine the association between serum 25-hydroxyvitamin D levels in patients with alopecia areata compared with healthy controls.</p><p><strong>METHODS:</strong> Observational studies on association of vitamin D levels on alopecia areata compared to healthy controls were obtained from all published articles until July 2018 on MEDLINE, Cochrane Library, TRIP, HERDIN, and Google. Review Manager 5.3 was used for the meta-analysis.</p><p><strong>RESULTS:</strong> The search strategy yielded 13 qualified articles for the full-length review and 11 studies, containing 916 patients, were included in the meta-analysis using the pooled random effects model. The pooled mean difference of the serum 25-hydroxyvitamin D levels between alopecia areata patients and healthy controls was -9.55 (95% CI, -10.51 to -8.59) with heterogeneity (I2=85%).</p><p><strong>CONCLUSION:</strong> In conclusion, there were reduced levels of serum 25-hydroxyvitamin D levels in alopecia areata compared to healthy controls and vitamin D deficiency was more prevalent in alopecia areata compared to healthy controls. There was also a trend of lower vitamin D levels in the more severe forms of alopecia.</p>

Intralesional measles, mumps, and rubella vaccine for cutaneous warts: A systematic review and meta-analysis

@#<p style="text-align: justify;"><strong>BACKGROUND: </strong>Warts, caused by the human papilloma virus (HPV), are mucocutaneous proliferations controlled by cell-mediated immunity. Intralesional immunotherapy with measles, mumps, and rubella (MMR) vaccine, is postulated to induce a higher immune response for clearance of lesions.<br /><strong>OBJECTIVE: </strong>To assess the efficacy, safety and effect on recurrence of intralesional MMR vaccine for the treatment of warts.<br /><strong>METHODS: </strong>We searched online databases for randomized controlled trials on intralesional MMR vaccine for warts. Effects measured were the complete clearance of target and distant warts, adverse events noted and recurrence after treatment duration.<br /><strong>RESULTS: </strong>Four RCTs comparing intralesional MMR vaccine and placebo were assessed. Meta-analysis showed a risk ratio of 0.24 [95% CI: 0.18, 0.34] favoring intralesional MMR vaccine and a highly significant difference in completely clearing target warts (P-value <0.00001) versus placebo. Three of the 4 trials assessed response of distant warts showing a risk ratio of 0.28 [95% CI: 0.08, 0.96] and a significant difference (P=0.04) versus placebo. Pain and flu-like symptoms were the most common side effects with no recurrence seen after 3-6 months.<br /><strong>CONCLUSIONS: </strong>Intralesional MMR vaccine significantly reduces and clears target and distant warts as compared to placebo. It is a generally safe intervention with lasting effect assessed up to 6 months follow-up.</p>